ERVMER34 sensitizes the response of HER2 positive breast cancer to neoadjuvant therapy

被引：0
|
作者：
Chi, Y. [1 ]
Ji, W. [1 ]
Xiu, B. [1 ]
Zhang, Q. [1 ]
Wu, J. [1 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-P5-03-13
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-03-13
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Next-generation sequencing based detection of HER2 copy number predicts pathological response to neoadjuvant therapy in HER2 positive breast cancer
    Dai, Hao
    Jiao, Dechuang
    Guo, Xuhui
    Qiao, Jianghua
    Li, Anfang
    Lu, Zhenduo
    Chen, Xiuchun
    Wang, Chengzheng
    Yan, Min
    Liu, Zhenzhen
    CANCER RESEARCH, 2023, 84 (06)
  • [32] Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients
    Guarneri, V.
    Dieci, M. V.
    Barbieri, E.
    Piacentini, F.
    Omarini, C.
    Ficarra, G.
    Bettelli, S.
    Conte, P. F.
    ANNALS OF ONCOLOGY, 2013, 24 (12) : 2990 - 2994
  • [33] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Wang, Yihong
    Singh, Kamaljeet
    Dizon, Don
    Graves, Teresa
    Amin, Ali
    Yakirevich, Evgeny
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 186 (03) : 667 - 676
  • [34] Immunohistochemical HER2 score correlates with response to neoadjuvant chemotherapy in HER2-positive primary breast cancer
    Yihong Wang
    Kamaljeet Singh
    Don Dizon
    Teresa Graves
    Ali Amin
    Evgeny Yakirevich
    Breast Cancer Research and Treatment, 2021, 186 : 667 - 676
  • [35] Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
    Zheng-Jun Yang
    Fei Xin
    Zu-Jin Chen
    Yue Yu
    Xin Wang
    Xu-Chen Cao
    BMC Cancer, 24
  • [36] Correlation between HER2 amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2 positive breast cancer.
    Antolin, Silvia
    Garcia-Caballero, Lucia
    Reboredo, Cristina
    Molina Diaz, Aurea
    Mosquera, Joaquin
    Vazquez-Boquete, Angel
    Gallego, Rosalia
    Paz Santiago, Maria
    Concha, Angel
    Eva Perez, Maria
    Calvo, Lourdes
    Garcia-Caballero, Tomas
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
  • [38] Real-world data on neoadjuvant chemotherapy with dual-anti HER2 therapy in HER2 positive breast cancer
    Yang, Zheng-Jun
    Xin, Fei
    Chen, Zu-Jin
    Yu, Yue
    Wang, Xin
    Cao, Xu-Chen
    BMC CANCER, 2024, 24 (01)
  • [39] Breast Cancer Biomarker Changes and Correlations with HER2 Change in ER Positive, HER2 Negative Breast Cancers Treated with Neoadjuvant Endocrine Therapy
    Huang, Wei
    Tyburski, Haley
    Finkelman, Brian
    Turner, Bradley
    Weiss, Anna
    Dhakal, Ajay
    Skinner, Kristin
    Hicks, David
    Zhang, Huina
    LABORATORY INVESTIGATION, 2024, 104 (03) : S175 - S176
  • [40] Prognostic significance and evolution of HER2 zero, HER2 low and HER2 positive in breast cancer after neoadjuvant treatment
    Wei, T.
    Wang, D.
    Peng, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S301 - S302
12345